etopophos and samarium-sm-153-lexidronam Interactions

You searched for interactions between:

• etopophos
• samarium-sm-153-lexidronam (samarium sm 153 lexidronam)

Interaction(s) found:

samarium sm 153 lexidronam and etoposide phosphate (Major Drug-Drug)

GENERALLY AVOID: Theoretical concerns exist that chemotherapeutic agents may potentiate the myelosuppressive effects of samarium sm 153 lexidronam. In clinical trials, white blood cell and platelet counts decreased to a nadir of approximately 40% to 50% of baseline in 95% of patients within three to five weeks after administration of samarium sm 153 lexidronam, and tended to return to pretreatment levels by eight weeks. The potential for additive bone marrow toxicity with chemotherapy or external beam radiation has not been studied.

MANAGEMENT: The manufacturer recommends that samarium sm 153 lexidronam not be given concurrently with chemotherapy or external beam radiation therapy unless benefits are anticipated to outweigh the risks. Samarium sm 153 lexidronam should not be given after either of these treatments until there has been time for adequate marrow recovery. Caution and close monitoring of bone marrow function are advisable if concurrent administration cannot be avoided. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.